divendres, 6 de març del 2015

GI Dynamics plunges 50% after FDA halts trial




Shares of GI Dynamics lose 50% of their value after the company reveals that the FDA halted enrollment a clinical trial of its EndoBarrier weight loss device.





GI Dynamics plunges 50% after FDA halts trial

Food & Drug Administration (FDA), GI Dynamics

News Well, Clinical Trials, Bariatrics, Regulatory/Compliance, Weight loss

read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1EuGvEk
a

Cap comentari:

Publica un comentari a l'entrada